secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0000950170-24-139121
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs
---------------------------------------------------------------------------

- CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.
- Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).
- No replacement appointed; company restructures clinical leadership without a CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/0000950170-24-139121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024139121/sndx-20241220.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-139121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer